

SWR, 16 June 2020

- <https://www.swr.de/swraktuell/baden-wuerttemberg/tuebingen/curevac-will-impfstoff-an-menschen-testen-100.html>

– Translation by Kilian Bluemlein, 86 AW/PA



BIOTECH COMPANY IS WAITING FOR PERMISSION

Corona: Tuebingen based Company plans Vaccine Testing on Humans

The biotech firm Curevac is apparently planning a clinical study of a corona vaccine. This would be the second one in Germany. Today details can be revealed.

As the second firm in Germany – after the competitor Biontech in the City of Mainz – Curevac wants to start a clinical study with a potential vaccine. According to information by ARD [publicly controlled nationwide TV station K.B.] Curevac expects permission by the responsible Paul-Ehrlich Institute soon. A prerequisite is that previous tests in the laboratory and on animals have been promising enough that people can be tested as well.

Permission for Testing has not been received

Reuters press agency also reports about that referring to insider information. Today Paul-Ehrlich Institute invited to a virtual media briefing to give updated information about further clinical testing of a COVID-19 vaccine.

At the end of April Paul-Ehrlich Institute had – for the first time in Germany - authorized a clinical study for Biontech's COVID-19 vaccine. Curevac announced to start first clinical studies with volunteers at good health.

At the beginning of this week Curevac made headlines when the Federal Administration had announced to invest 300 million euro in Curevac through its KfW business development bank. This is to accelerate development of a vaccine against the rampant corona virus. The U.S. Administration was also said to have had an interest in the firm.

Vaccine is sought for on a world-wide Level

Throughout the world the pharmacological industry is feverishly seeking a vaccine and medication against the new corona virus. An entire series of vaccine projects are being tested on humans. One of the leading companies is U.S. biotech group Moderna which started its clinical study in the middle of March.

Just like Biontech and Curevac Moderna specialized in vaccines based on the so-called messenger RNA. The vaccine is to transmit information into cells so that they produce proteins and thereby fight the virus. A vaccine on this base may possibly be developed and produced faster than conventional vaccines.

As of June 16, 21.15 p.m.